Applied DNA Sciences (“Applied DNA”) is a biotechnology company with over 20 years of experience in developing and commercializing polymerase chain reaction (PCR)-based applications for DNA production. Through our majority-owned subsidiary, LineaRx Inc., we are commercializing a differentiated, synthetic DNA approach to the manufacture of next-generation nucleic acid-based therapies.
The Company was reincorporated in Delaware in 2008.
Applied DNA Sciences, Inc.
50 Health Sciences Drive
Stony Brook, NY 11790
Tel +1-631-240-8800
Fax +1-631-240-8900
The Company’s fiscal year begins on October 1 and ends on September 30. By quarter: Q1 is October 1-December 31, Q2 is January 1-March 31, Q3 is April 1-June 30, and Q4 is July 1-September 30.
As of July 31, 2025, shares outstanding totaled 1,201,465.
Applied DNA’s shares are traded on the NASDAQ Capital Market under the ticker symbol “APDN.
You can view us by visiting the Management Team page.
Our press release archive can be viewed in the Press Releases section, and filings are available in the SEC Filings section.
CBIZ CPAs P.C.
68 South Service Road
Suite 300
Melville, N.Y. 11747
(631) 414-4000
Equiniti Trust Company
Tel: (800) 937-5449OR (718) 921-8124
URL: https://equiniti.com/us/ast-access/individuals/
The transfer agent is responsible for maintaining all records of stockholders (including change of address, telephone number, and name), canceling or issuing stock certificates, and resolving problems related to lost, destroyed, or stolen certificates.
Email us at investors@adnas.com, and we will respond as soon as possible.
Sanjay M. Hurry
Executive Director, Investor Relations and Corporate Communications
hurry@adnas.com
M: 917-733-5573
Please visit the Investor Email Alerts section to be added to our investor email distribution list.